IDT
$17MCF+
IDT Australia
Radiopharmaceuticals
cGMP contract development and manufacturing organisation (CDMO) providing API synthesis, specialty oral dosage, and radiopharmaceutical manufacturing.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.9M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$17M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
427M
Pipeline Assets
3
Latest Insight(1)
26 Mar 2026Insider TradeChange of Director's Interest Notice - MS
2 transactions·+$15k net buySimari: bought $15k
3M Price
IDT.ASX$0.040-18.4% 3M
Low $0.040High $0.054
Pipeline Assets (3)
Radiopharmaceutical CDMOContract radiopharmaceutical manufacturing
ApprovedSpecialty Oral CDMOContract formulation and manufacturing
ApprovedAdvanced Therapies CDMOSterile injectables and mRNA manufacturing
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
5 transactionsLast 90dNet Buy
Buys5+5 vs prior
Sells0
Buy Value$77k
$11,5742026-03-24
98d before · New radiopharmaceutical CDMO contract wins
BUY
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (2)
New radiopharmaceutical CDMO contract wins
UpcomingSpeculativearrow_upwardHigh30 June 2026
FY2026 full year results — potential first profitable year
UpcomingSpeculativearrow_upwardHigh31 Aug 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| New radiopharmaceutical CDMO contract wins | commercial milestone | Speculative | arrow_upwardHigh | 30 June 2026 |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.